Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment ...
Submission included data from the Phase 3 QUASAR program in ulcerative colitis and the Phase 3 GALAXI program in Crohn's disease, which each achieved their primary endpoints1,2 BEERSE, Belgium, May 1, 2024 /PRNewswire/ -- Janssen-Cilag …